Latest News
Annexon, Inc.
- Why Is Annexon (NASDAQ:ANNX) Up 2.74% Pre-Market on Tuesday? The Catalyst, the Fundamentals and What Comes Next
- Why Did Annexon (NASDAQ:ANNX) Surge 9.94% on Monday? The Catalyst, the Fundamentals and What Comes Next
- Annexon Reports Inducement Grants to New Employees
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- Annexon: Preserving Patient Function Is The Real Investment Opportunity (NASDAQ:ANNX)
- Annexon shifts focus to preserving patient func...
- Insider Spends US$100k Buying More Shares In Annexon
- Annexon to present new data from ARCHER and ARCHER II trials in geographic atrophy at Retina Society meeting
- Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
- More than 8 million people have an eye disease that can cause blindness. Annexon will present trial findings.
- Annexon presents vonaprument data at retina meeting
Headlines from the last 30 days, linking to the original publishers. See all market news →